Introduction {#s1}
============

The intestinal microbiota plays a crucial role in the maintenance of host homeostasis by shaping and supporting multiple physiological functions, such as nutrient absorption, metabolism, and the development of the immune system ([@bib9]; [@bib37]; [@bib42]; [@bib43]; [@bib55]). The microbiota also outcompetes intestinal colonization by microbial pathogens and thus provides an exogenous defense mechanism against infections ([@bib38]; [@bib44]). Indeed, quantitative and/or qualitative changes in the composition of the microbiota, known as dysbiosis, are associated with expansion of pathobionts, damage to the intestinal epithelium, bacterial translocation into deeper organs, and ultimately development of numerous pathologies ([@bib14]; [@bib21]; [@bib47]).

*Clostridium difficile* is an anaerobic bacterium that forms spores, which can be found in the intestines of up to 17% of healthy adult individuals. *C. difficile* is resistant to several antimicrobial agents, including clindamycin, ampicillin, and third-generation cephalosporins, and hence acquires a selective advantage over other microorganisms during antibiotic therapy ([@bib21]; [@bib36]; [@bib47]). Thus, antibiotic-induced dysbiosis can lead to *C. difficile* infections (CDIs) that cause intestinal disease ranging from mild diarrhea to pseudomembranous colitis ([@bib6]; [@bib36]; [@bib47]). *C. difficile* exerts pathogenicity through spore germination and production of toxins, particularly toxins A (enterotoxin) and B (cytotoxin), which cause irreversible damage to the colonic epithelium ([@bib3]; [@bib53]). Loss of epithelial integrity results in increased intestinal permeability and translocation of bacteria from the gut lumen into deeper tissues ([@bib17]; [@bib32]). Emphasizing the importance of healthy microbiota in preventing CDI, several studies have demonstrated that patients with recurrent CDI benefit more from transplantation of fecal microbiota derived from healthy donors than from conventional antimicrobial therapies ([@bib26]; [@bib49]).

Innate immune responses are essential for host resistance against CDI. Neutrophils provide an early line of defense: once recruited into the intestinal mucosa, neutrophils carry out several protective functions, such as producing reactive oxygen species ([@bib11]) and secreting IL-1β ([@bib17]). Depletion of neutrophils in mice results in acute mortality following infection ([@bib20]). Two subsets of innate lymphoid cells (ILCs) have also been shown to contribute to early host defense against *C. difficile* ([@bib1]). ILC1s secrete IFNγ, which activates macrophage defense functions; ILC3s secrete IL-22, which induces the production of antimicrobial peptides in the gut ([@bib39]) and activates the complement pathway in the lung and liver to clear translocated bacteria ([@bib18]). The importance of ILCs in CDI is underscored by the observation that *Rag1*^−/−^ mice, which lack T and B cells, can recover from acute infection as well as WT mice, whereas *Rag1*^−/−^ × *Il2rg*^−/−^ mice, which lack ILCs as well as adaptive lymphocytes, succumb to infection ([@bib1]; [@bib18]).

Production of short-chain fatty acids (SCFAs) through the fermentation of dietary fibers is a major mechanism through which the microbiota promotes intestinal immunity ([@bib8]). SCFAs include acetate, propionate, and butyrate; these molecules can act through disparate mechanisms, such as activating specific G protein--coupled receptors, inhibiting histone deacetylases, stimulating histone acetyltransferase, and stabilizing hypoxia inducible factor 1 ([@bib10]; [@bib13]; [@bib23]; [@bib24]; [@bib51]). Through these pathways, SCFAs influence multiple immune cell functions, including chemotaxis, energy production, gene expression, cell differentiation, and cell proliferation ([@bib10]; [@bib13]; [@bib23]; [@bib24]; [@bib46]; [@bib51]). While the role of SCFAs has been studied in various proinflammatory and antiinflammatory intestinal immune responses ([@bib10]; [@bib15]; [@bib16]; [@bib22]; [@bib24]; [@bib30]), only the impact of butyrate was recently demonstrated during CDI ([@bib12]). The influence of other SCFAs on immune responses against *C. difficile* is presently unknown.

Here, we examined the impact of acetate on an acute mouse model of CDI. We found that administration of acetate is remarkably beneficial in ameliorating disease. Mechanistically, we show that acetate enhances innate immune responses by acting on both neutrophils and ILC3s through its cognate receptor free fatty acid receptor 2 (FFAR2). In neutrophils, acetate-FFAR2 signaling facilitates inflammasome activation and promotes the release of IL-1β; in ILC3s, acetate-FFAR2 augments expression of the IL-1 receptor (IL-1R), which boosts IL-22 secretion in response to IL-1β. We conclude that microbiota-derived acetate promotes host innate responses to *C. difficile* through coordinate action on neutrophils and ILC3s.

Results {#s2}
=======

A fiber-rich diet and oral administration of acetate protect mice against CDI {#s3}
-----------------------------------------------------------------------------

We tested the clinical course of CDI in WT mice fed a soluble fiber-rich diet (10% pectin) in comparison to mice fed control diet (AIN93M; [Fig. 1 A](#fig1){ref-type="fig"}). Mice fed the pectin-rich diet had improved clinical scores and lost less weight than mice fed the control diet ([Fig. 1, B and C](#fig1){ref-type="fig"}). The protective effect of the fiber-rich diet was associated with an increase in intestinal bacteria content ([Fig. S1 A](#figS1){ref-type="fig"}), as well as higher concentrations of acetate in serum ([Fig. 1 D](#fig1){ref-type="fig"}). Because acetate is a metabolite produced by intestinal bacteria through soluble fiber fermentation, this suggests that bacterial-derived acetate may be protective during CDI. Corroborating this hypothesis, addition of 150 mM acetate to the drinking water before and throughout the infection was sufficient to protect mice against CDI, resulting in improved clinical scores and less-severe weight loss ([Fig. 1, E--G](#fig1){ref-type="fig"}) without impacting intestinal bacterial content ([Fig. S1 B](#figS1){ref-type="fig"}). Histologically, we observed increased inflammatory infiltrate in acetate-treated mice 2 d postinfection (p.i.) as well as attenuated histopathology and mucosal hyperplasia 4 d p.i. ([Fig. 1 H](#fig1){ref-type="fig"}). Since acetate did not inhibit *C. difficile* growth ([Fig. S1 C](#figS1){ref-type="fig"}) or toxin production in vitro or in vivo (not depicted) and had rapid course of action by improving clinical scores and weight loss even when it was administered at the time of infection ([Fig. S1, D--F](#figS1){ref-type="fig"}), we conclude that acetate improves host resistance to *C. difficile* rather than directly interfering with bacterial replication.

![**High-fiber diet (HFD) and acetate administration protect against CDI.** **(A)** WT mice were fed a HFD or low-fiber diet (LFD) before and throughout the experiment. Mice were treated with a mix of antibiotics for 4 d and then received a single i.p. dose of clindamycin. 1 d later, mice were infected with 10^8^ CFU of *C. difficile* (day 0). **(B and C)**Mice were monitored for clinical score (B) and weight change (C) until day 5 p.i. **(D)** Serum SCFA concentrations were measured on day 0 before infection (*n* = 5). **(E)** Mice received 150 mM acetate in the drinking water from 1 d before antibiotic treatment until the end of the infection. **(F and G)**Mice were monitored for clinical score (F) and weight change (G; *n* = 10). **(H)** Representative histological sections of colons stained with hematoxylin and eosin and blinded histopathological scoring of mice on day 2 and 4 p.i. that were either treated (Ac) or not (Ct) with acetate (*n* = 4). Scale bars = 200 µm. Results are representative of two independent experiments with four to five mice in each experimental group (A--C and H) or pooled results from two experiments with four to five mice in each experimental group (D--G). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig1){#fig1}

![**Acetate protects against CDI through NLRP3 activation. (A and B)** Analysis by qPCR of relative bacterial load in the feces. Mice were fed with a HFD or LFD before and after antibiotic treatment and analyzed on day 0 before infection (A; *n* = 10); or treated (Ac) or not (Ct) with acetate in the drinking water throughout the experiment and analyzed on day 2 p.i (B; *n* = 6). The bar indicates median ± minimum to maximum. **(C)** In vitro growth of *C. difficile* measured by optical density at 600 nm in the presence of different concentrations of acetate (*n* = 15). The dashed line represents the optical density of culture medium without bacteria. **(D--F)** WT mice were treated with a mix of antibiotics for 4 d and then received a single i.p. dose of clindamycin. 1 d later (day 0), mice started to receive 150 mM acetate in the drinking water and were infected with 10^8^ CFU of *C. difficile*. Mice were monitored for clinical symptoms (E) and weight changes (F) until day 6 p.i. (*n* = 5). **(G--I)** Clinical score (G), body weight variations (H), and intestinal permeability (I) of *Nlrp3*^−/−^ and WT mice that were treated or not with acetate and infected with *C. difficile* (*n* = 5--6). **(J--L)** Clinical score (J), body weight variations (K), and intestinal permeability (L) of *Nlrc4*^−/−^ mice treated or not with acetate and infected with *C. difficile* (*n* = 6). *Nlrp3*^−/−^, *Nlrc4*^−/−^, and WT mice were bred in the same animal facility, matched for sex and age, and infected at the same time to avoid batch effects. WT graphs included with *Nlrp3*^−/−^ and *Nlrc4*^−/−^ graphs are the same included with *Casp1/11*^−/−^ graphs (see [Fig. 3](#fig3){ref-type="fig"}) and are presented in all figures for comparison. **(M and N)** Clinical score (M) and body weight variations (N) of *Nlrp6*^−/−^ mice that were treated or not with acetate and infected with *C. difficile* (*n* = 5). WT graphs included with *Nlrp6*^−/−^ graphs are the same included with *Il22*^−/−^ data (see [Fig. 5](#fig5){ref-type="fig"}) and shown in both figures for comparison. **(O)** Analysis of intestinal permeability of *Nlrp6*^−/−^ mice on day 2 p.i. (*n* = 5). **(P)** Relative bacterial load translocated to the peripheral organs on day 2 p.i. in *Nlrp6*^−/−^ mice treated or not with acetate (*n* = 5). Results are representative of two independent experiments with four mice in each experimental group (B and D--F) or pooled results from two experiments with five mice in each group (A), three experiments with five replicates in each one (C), or one experiment with five to six mice in each group (G--P). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_FigS1){#figS1}

Acetate enhances neutrophil accumulation and prevents bacterial translocation {#s4}
-----------------------------------------------------------------------------

We next examined the impact of acetate on the host response to CDI. Neutrophils have been shown to be crucial early during the host response to *C. difficile* ([@bib20]). In accordance with the histological observations, as early as 1 d p.i., mice treated with acetate had more neutrophils infiltrating the colon, but not inflammatory monocytes, than untreated controls ([Figs. 1 H](#fig1){ref-type="fig"}and [2, A and B](#fig2){ref-type="fig"}). This initial effect of acetate treatment was associated with more colonic content of CXCL1, a neutrophil chemoattractant produced by intestinal epithelia and neutrophils themselves ([Fig. 2 C](#fig2){ref-type="fig"}). The colons of acetate-treated mice also contained more IL-1β ([Fig. 2 C](#fig2){ref-type="fig"}), a cytokine produced by intestinal epithelia and neutrophils that has a prominent role in impeding the translocation of gut bacteria and their systemic dissemination ([@bib17]). The content of proinflammatory TNFα was slightly reduced ([Fig. 2 C](#fig2){ref-type="fig"}). Consistent with the increase in neutrophil infiltration and IL-1β production, acetate-treated mice showed a detectable reduction of bacteria translocation into mesenteric lymph nodes (mLNs) on day 1 p.i., which became obvious in several organs on day 2 p.i. ([Fig. 2, D and E](#fig2){ref-type="fig"}). Further substantiating a role in protecting the intestinal mucosa from CDI-induced damage, acetate also curtailed systemic permeability of FITC-dextran after oral administration in infected mice ([Fig. 2 F](#fig2){ref-type="fig"}). In vitro, acetate did not prevent intestinal epithelial cell death by *C. difficile* toxins, as measured by propidium iodide and calcein-AM staining ([Fig. 2, G and H](#fig2){ref-type="fig"}). Together, these data suggest that acetate bolsters host resistance to *C. difficile*--mediated intestinal damage by enhancing early intestinal immune responses, such as neutrophil accumulation and production of IL-1β.

![**Acetate increases colonic neutrophil recruitment and IL-1β content during CDI.** **(A and B)** Representative plots (A) and absolute number of neutrophils and inflammatory monocytes in the colonic lamina propria (B) of naive and *C. difficile*--infected mice on day 1 p.i. (*n* = 4). **(C)** Quantification of cytokines in colon samples on day 1 p.i. Mice were treated (Ac) or not (Ct) with acetate in the drinking water. Results are normalized according to the tissue weight (*n* = 8). **(D and E)** Bacterial translocation into the mLNs, spleen, and liver assessed by qPCR on day 1 (D) or 2 (E) p.i. (*n* = 5--7). **(F)** Analysis of intestinal permeability using FITC-dextran. Mice received FITC-dextran by gavage on day 1 p.i. Serum samples were collected 4 h later (*n* = 4). **(G and H)** Effect of acetate on the intestinal epithelial cell line HCT-116 exposed to supernatant containing *C. difficile* toxins. **(G)** Percentage of live cells after 48 h of incubation with *C. difficile* supernatant ± acetate at 25, 50, and 100 µM (*n* = 10--13). Cells lysed with Triton X-100 were included as control. **(H)** Images of HCT-116 monolayer stained with Hoechst (blue, nucleus), calcein-AM (green, viable cells), and propidium iodide (red, dead cells) after 48 h of incubation with *C. difficile* supernatant ± acetate (*C. diff* sup ± Ac) at 25 µM. Scale bars = 100 µm. Results are representative of at least two independent experiments with three to four mice in each experimental group (A and E), pooled results from two independent experiments with two to four mice in each experimental group (B--D), and three experiments with three to five replicates in each group (F and G). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig2){#fig2}

The protective effect of acetate depends on inflammasome activation {#s5}
-------------------------------------------------------------------

It has been shown that *C. difficile* toxins trigger IL-1β production through inflammasome activation. *C. difficile* toxins glucosylate RhoA-GTPase, activating the Pyrin inflammasome ([@bib54]). In addition, they trigger the NLRP3 inflammasome through an as-yet-undefined mechanism, perhaps by inducing reactive oxygen species ([@bib33]). To determine whether acetate enhances inflammasome activation, we examined the impact of acetate on CDI in mice lacking either the effector caspase-1 or one of various inflammasomes implicated in caspase-1 activation. The beneficial effect of acetate on clinical score, weight change, and intestinal permeability during CDI was abrogated in *Casp1/11*^−/−^ mice ([Fig. 3, A--C](#fig3){ref-type="fig"}), as well as *Nlrp3*^−/−^ mice, which lack one of the inflammasomes that sense *C. difficile* toxins ([Fig. S1, G--I](#figS1){ref-type="fig"}). In contrast, acetate maintained its protective effect in *Nlrc4*^−/−^ mice and in large part, in *Nlrp6*^−/−^ mice ([Fig. S1, J--P](#figS1){ref-type="fig"}). Acetate also failed to prevent translocation of bacteria into the liver, spleen, or mLNs of *Casp1/11*^−/−^ mice ([Fig. 3 D](#fig3){ref-type="fig"}). Additionally, acetate did not enhance the content of IL-1β, CXCL1 ([Fig. 3 E](#fig3){ref-type="fig"}), or neutrophil infiltration ([Fig. 3 F](#fig3){ref-type="fig"}) in the colons of *Casp1/11*^−/−^ mice. Since caspase-1 activation also triggers IL-18 production, we examined the impact of acetate on IL-18 during CDI. Increased amounts of IL-18 were detected in the colons of WT mice on day 1 p.i. ([Fig. S2 A](#figS2){ref-type="fig"}). However, acetate did not enhance colonic IL-18 content in *Casp1/11*^−/−^ mice, providing further evidence that acetate acts by promoting inflammasome-regulated cytokine production during CDI.

![**Acetate augments caspase-1 activation and IL-1β secretion in response to *C. difficile* toxins.** **(A--C)** Clinical score (A), body weight changes (B), and intestinal permeability (C) in *Casp1/11*^−/−^ and WT mice that were treated (Ac) or not (Ct) with acetate and infected with *C. difficile* (*n* = 5--6). *Casp1/11*^−/−^ and WT were bred in the same animal facility, matched for sex and age, and infected at the same time to avoid batch effects. **(D)** Bacterial translocation into the peripheral organs in *Casp1/11*^−/−^ and WT mice on day 1 p.i. (*n* = 6). **(E)** Quantification of IL-1β and CXCL1 in colon samples of *Casp1/11*^−/−^ and WT mice on day 1 p.i. Results were normalized according to sample weight (*n* = 6). **(F)** Absolute numbers of CD11b^+^Ly6G^+^ neutrophils in the colonic lamina propria of *Casp1/11*^−/−^ mice and WT mice on day 1 p.i. (*n* = 6). **(G)** Quantification of IL-1β production by neutrophils in vitro. Neutrophils were incubated with or without LPS ± acetate, followed by stimulation in vitro with supernatant containing whole *C. difficile* (C.diff), toxin-containing supernatant (sup), or medium as indicated (*n* = 8). **(H)** IL-1β production by neutrophils after incubation in vitro with LPS, *C. difficile* supernatant, and either caspase-1 inhibitor (Q-VD-OPh), elastase inhibitor (Sivelestat; *n* = 6), or DMSO (control). Results are representative of two independent experiments with three to six mice in each experimental group (A, B, E, and F), one experiment with six mice in each group (C and D), or pooled results from two independent experiments with three to four mice in each group (G and H). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig3){#fig3}

![**Acetate augments IL-1β and IL-18 secretion in response to *****C. difficile***** toxins. (A)** IL-18 content in the colon of WT and *Casp1/11*^−/−^ mice that were treated (Ac) or not (Ct) with acetate (*n* = 5--6). Mice were examined on day 1 p.i. The results were normalized according to sample weight. **(B)** Neutrophil viability measured by 7-AAD and Annexin-V staining before and after 6-h in vitro incubation. Neutrophils were isolated from bone marrow and stimulated as follows: 0 h, staining after BM isolation; U.V., 1 min ultraviolet irradiation and then 6-h incubation; Azide 1%, 6-h incubation in 1% sodium azide medium; Ct, 6-h culture in RPMI and 10% bovine calf serum; Ac, 6-h incubation in medium with 25 mM acetate; Ct (LPS + sup), 2 h of incubation with LPS, followed by 4 h with *C. difficile* supernatant; Ac (LPS + sup), 2 h of incubation with LPS + acetate, followed by *C. difficile* supernatant (*n* = 6). **(C)** IL-18 content in the colon of *Ffar2*^−/−^ mice that were treated or not with acetate and infected with *C. difficile* (*n* = 5--6). Mice were examined on day 1 and 5 p.i. **(D)** IL-1β production by neutrophils after incubation in vitro with LPS ± acetate followed by stimulation with *C. difficile* supernatant. Neutrophils were isolated from the bone marrow of WT and *Ffar2*^−/−^ mice by FACS sorting CD11b^+^Ly6G^+^ cells (*n* = 12). **(E)** IL-1β production by neutrophils in vitro from bone marrow of WT or *Ffar2*^−/−^ mice. Neutrophils were preincubated with LPS ± acetate and then stimulated with *C. difficile* supernatant together with nigericin and BAPTA-AM or together with nigericin and KCl (*n* = 6). Results are representative of at least two independent experiments with four to five mice in each experimental group (A) or pooled results from two independent experiments with three to five mice in each experimental group (B--E). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_FigS2){#figS2}

Acetate augments inflammasome activation and IL-1β secretion in neutrophils {#s6}
---------------------------------------------------------------------------

Given the major role of neutrophils in IL-1β secretion and in controlling bacterial translocation during CDI ([@bib17]; [Fig. 2](#fig2){ref-type="fig"}), we wanted to examine the effects of acetate on inflammasome activation by *C. difficile* in neutrophils. Stimulation of neutrophils purified from the bone marrow of WT mice with acetate markedly potentiated the production of IL-1β in response to *C. difficile* or its supernatant containing a defined amount of toxins ([Fig. 3 G](#fig3){ref-type="fig"}), without affecting neutrophil viability ([Fig. S2 B](#figS2){ref-type="fig"}). The enhancing effect of acetate on IL-1β secretion was evident whether or not neutrophils were primed with LPS ([Fig. 3 G](#fig3){ref-type="fig"}). Moreover, acetate effect was blocked by an inhibitor of caspase-1, whereas it was unaffected by an inhibitor of neutrophil elastase ([Fig. 3 H](#fig3){ref-type="fig"}). We conclude that acetate augments inflammasome-regulated IL-1β secretion by neutrophils in response to *C. difficile* toxins.

The protective effect of acetate during CDI is FFAR2 dependent {#s7}
--------------------------------------------------------------

Among various mechanisms, acetate can modulate cell functions through activation of FFAR2 (also known as GPR43) in epithelial cells and neutrophils ([@bib8]). Given that acetate generates faster outcomes through FFAR2 signaling than through other mechanisms requiring chromatin remodeling, and that acetate acts rapidly during CDI ([Fig. S1, D--F](#figS1){ref-type="fig"}), we sought to examine the impact of FFAR2 in acetate-mediated protection against CDI. We found that the beneficial effects of acetate on clinical score, weight change, systemic translocation of bacteria, and intestinal permeability during CDI were abrogated in *Ffar2*^−/−^ mice ([Fig. 4, A--D](#fig4){ref-type="fig"}). Additionally, the increased colonic content of CXCL1, IL-1β, and IL-18; the enhanced infiltration of neutrophils in the colon; and the reduced systemic bacterial translocation mediated by acetate in WT mice were not evident in *Ffar2*^−/−^ mice ([Fig. 4, E--G](#fig4){ref-type="fig"}; and [Fig. S2 C](#figS2){ref-type="fig"}). Together, these findings suggest that the effects of acetate on host resistance to CDI depend on FFAR2.

![**Acetate acts through FFAR2.** **(A and B)** Clinical score (A) and weight changes (B) of *Ffar2*^−/−^ and WT mice infected with *C. difficile* and treated (Ac) or not (Ct) with acetate (*n* = 3--6). *Ffar2*^−/−^ and WT littermates were infected at the same time. **(C)** Bacterial translocation into peripheral organs 2 d p.i. in *Ffar2*^−/−^ treated or not with acetate (*n* = 3). **(D)** Intestinal permeability in *Ffar2*^−/−^ mice treated or not with acetate (*n* = 4). **(E--G)** Cytokine content (E), neutrophil percentage (F), and bacterial load translocated into the peripheral organs (G) on day 1 p.i. in WT or *Ffar2*^−/−^ mice treated with acetate (*n* = 5). **(H)** IL-1β production by WT and *Ffar2*^−/−^ neutrophils after priming in vitro with LPS ± acetate followed by stimulation with *C. difficile* supernatant (*C. diff* sup; *n* = 8). **(I)** IL-1β production by WT and *Ffar2*^−/−^ neutrophils after incubation in vitro with LPS ± acetate followed by stimulation with Nigericin or no stimulation (*n* = 8). **(J and K)** IL-1β production by neutrophils from WT and *Ffar2*^−/−^ mice. Cells were preincubated with LPS ± acetate for 2 h as indicated, and then stimulated with *C. difficile* supernatant ± BAPTA-AM (J); *C. difficile* supernatant ± KCl (K); or *C. difficile* supernatant ± NaCl (L; *n* = 6). Results are representative of at least two independent experiments with three to five mice in each experimental group (A--G) or pooled results from two independent experiments with three to four mice in each group (H--K). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig4){#fig4}

FFAR2 enhances neutrophil secretion of IL-1β in an inflammasome-dependent fashion {#s8}
---------------------------------------------------------------------------------

We sought to determine whether acetate enhances neutrophil production of IL-1β through FFAR2. We prepared neutrophils by density gradient centrifugation from the bone marrow of WT and *Ffar2*^−/−^ mice, primed them in vitro with LPS in the presence or absence of acetate, stimulated them with *C. difficile* toxins, and then measured IL-1β production. The ability of acetate to augment IL-1β production by neutrophils was entirely dependent on FFAR2 ([Fig. 4 H](#fig4){ref-type="fig"}). Similar results were obtained using neutrophils highly purified from bone marrow by cell sorting ([Fig. S2 D](#figS2){ref-type="fig"}). We also tested whether acetate could enhance IL-1β production by neutrophils that are stimulated with a known inflammasome activator, the potassium (K^+^) ionophore nigericin. Indeed, acetate enhanced the K^+^ efflux--induced IL-1β production, and this effect was dependent on FFAR2 ([Fig. 4 I](#fig4){ref-type="fig"}). Thus, acetate enhances inflammasome activation and IL-1β secretion in neutrophils through FFAR2.

We further corroborated that acetate-FFAR2 signaling enhances IL-1β production in neutrophils through inflammasome activation. Treatment of neutrophils with BAPTA-AM (1,2-bis(*o*-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetic acid acetyloxymethyl ester), which inhibits NLRP3 by blocking Ca^2+^ influx, abrogated the ability of acetate to potentiate IL-1β production through FFAR2 signaling in response to LPS and *C. difficile* toxins or nigericin ([Figs. 4 J](#fig4){ref-type="fig"} and [S2 E](#figS2){ref-type="fig"}). A similar result was obtained by treating neutrophils with extracellular KCl, which inhibits NLRP3 by blocking K^+^ efflux ([Figs. 4 K](#fig4){ref-type="fig"} and [S2 E](#figS2){ref-type="fig"}). In contrast, incubation of neutrophils with NaCl, which boosts inflammasome activation by promoting K^+^ efflux, facilitated acetate enhancement of IL-1β production through FFAR2 ([Fig. 4 K](#fig4){ref-type="fig"}). Taken together, these results suggest that the ability of acetate--FFAR2 axis to potentiate the production of IL-1β in response to *C. difficile* toxins depends on inflammasome activation.

Acetate-mediated protection during CDI depends on IL-22 producing ILC3 {#s9}
----------------------------------------------------------------------

It has been shown that ILC3s protect from CDI through IL-22 production ([@bib1]; [@bib18]). Moreover, ILC3s express high amounts of FFAR2 ([Fig. S3 A](#figS3){ref-type="fig"} and <http://www.immgen.org>). Therefore, we asked whether acetate also impacts this protective mechanism. We found that acetate treatment increased the expression of *Rorc* and *Il22* in the colon of WT mice 2 d p.i. ([Fig. 5 A](#fig5){ref-type="fig"}), as well as IL-22 target genes (*Bcl2*, *Ccnd1*, *Reg3g*, *Muc1*, and *Muc4*) 5 d p.i. ([Fig. S3 B](#figS3){ref-type="fig"}). Increased amounts of IL-22 protein were detected in the colons of WT mice but not *Ffar2*^−/−^ mice on day 5 p.i. ([Fig. 5 B](#fig5){ref-type="fig"}), suggesting that acetate may promote IL-22 production through FFAR2. Although IL-22 was previously shown to be primarily produced by ILC3s during CDI ([@bib1]), whether acetate enhances IL-22 secretion by ILC3s and/or T cells was not clear. To address this question, we examined the impact of acetate in *Rag2*^−/−^ and *Rag2*/*Il2rg*^−/−^ mice with CDI. The protective effect of acetate was evident in *Rag2*^−/−^ mice, which lack T and B lymphocytes but retain ILCs, whereas it was undetectable in *Rag2*/*Il2rg*^−/−^ mice, which lack both innate and adaptive lymphocytes ([Fig. 5, C--F](#fig5){ref-type="fig"}). Reduction of intestinal permeability by acetate was also maintained in *Rag2*^−/−^ but not *Rag2*/*Il2rg*^−/−^ mice ([Fig. 5, G and H](#fig5){ref-type="fig"}). Thus, acetate-mediated protection of infected mice depends on ILCs.

![**The protective effect of acetate against CDI depends on ILC3s.** **(A)** *Rorc*, *Il22*, and *Il17* mRNA expression in the colon of WT mice on day 2 p.i. Mice were treated (Ac) or not (Ct) with acetate and infected with *C. difficile* (*n* = 5). **(B)** IL-22 content in the colon of WT and *Ffar2*^−/−^ mice on day 5 p.i. Mice were treated or not with acetate and infected with *C. difficile* (*n* = 5--6). **(C--F)** Clinical score and weight changes of *Rag2*^−/−^ mice (C and D) and *Rag2*/*Il2rg*^−/−^ mice (E and F) that were treated or not with acetate and infected with *C. difficile* (*n* = 4). **(G and H)** Intestinal permeability of *Rag2*^−/−^ (G) and *Rag2*/*Il2rg*^−/−^ (H) mice treated or not with acetate on day 2 p.i. (*n* = 4). **(I)** Percentages of total lymphocytes, natural killer (NK) cells, ILC1s, ILC2s, and ILC3s in the colon of mice 5 d p.i. (*n* = 7--8). A representative flow cytometry plot depicting the strategy for identifying NK-ILC subsets is presented at the top. Results are pooled results from two independent experiments with three to six mice in each group (A, B, and I). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig5){#fig5}

![**Acetate increases ILC3s number and activity during CDI. (A)** SCFA receptor expression in ILC subsets. RNA sequencing data available at <http://www.immgen.org>. **(B)** IL-22 target genes expression in the colon of WT mice on day 5 p.i. Mice were treated (Ac) or not (Ct) with acetate and infected with *C. difficile* (*n* = 7--8). **(C)** Percentages of total lymphocytes, natural killer (NK), ILC1, ILC2, and ILC3 subsets in the small intestine (si) from mice 5 d p.i. (*n* = 7--8). A representative flow cytometry plot depicting the strategy to identify the subsets is presented on the top. **(D)** Representative histological sections of colons stained with hematoxylin and eosin of ILC3-deficient mice on day 5 p.i. treated or not with acetate (*n* = 3). Scale bars = 200 µm. Results are representative of at least two independent experiments with three mice in each experimental group (D) or pooled results from two independent experiments with three to four mice in each experimental group (B and C). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_FigS3){#figS3}

We next examined the impact of acetate on the abundance of ILC subsets on day 5 p.i. Acetate-treated mice showed a moderate increase in the number of ILC3s, but not of other ILCs, in the colon ([Fig. 5 I](#fig5){ref-type="fig"}) and small intestine ([Fig. S3 C](#figS3){ref-type="fig"}). To validate that acetate-mediated protection is dependent on ILC3s, we infected *AhR^f/f^ Rorc-Cre* mice, which have a strong reduction of ILC3s ([@bib41]). We found that the beneficial effects of acetate on clinical score, weight change, colon length, intestinal permeability, and systemic translocation of bacteria during CDI were strongly reduced in the absence of ILC3s ([Fig. 6, A--F](#fig6){ref-type="fig"}). These mice also did not show clinical recovery and mucosal hyperplasia on day 5, in contrast to what normally occurs in WT mice ([Fig. 6, A and B](#fig6){ref-type="fig"}; and [Fig. S3 D](#figS3){ref-type="fig"}), indicating that ILC3s are important not only to mitigate the disease but also for a complete resolution.

![**IL-22--producing ILC3s are essential for acetate-mediated protection during CDI.** **(A--D)** Clinical score (A), body weight changes (B), colon length (C), and intestinal permeability (D) in ILC3-sufficient (*AhR^fl/fl^*) and -deficient (*AhR^fl/fl^* × *Rorc-Cre*) mice that were treated (Ac) or not (Ct) with acetate and infected with *C. difficile* (*n* = 5--8). *AhR^fl/fl^* × *Rorc-Cre* and *AhR^fl/fl^* littermates were infected at the same time. **(E and F)** Bacterial translocation into the liver (E) and spleen (F) in ILC3-sufficient and -deficient mice treated or not with acetate and infected with *C. difficile*. Samples were collected 5 d p.i., plated in blood agar, and incubated for 4 d at 37°C in aerobic or anaerobic conditions (*n* = 5--8). **(G)** Infected mice were treated with or without acetate and received an i.p. dose of anti--IL-22 neutralizing antibody or isotype (iso) control IgG2a on days 1 and 3 p.i. **(H and I)**Mice were monitored for clinical score (H) and weight change (I) until day 5 p.i. (*n* = 5). **(J and K)** Clinical score (J) and weight changes (K) of *IL22*^−/−^ and WT mice infected with 10^8^ CFU of *C. difficile* that were either treated or not with acetate (*n* = 5--6). *IL22*^−/−^ and WT mice were bred in the same animal facility, matched for sex and age, and infected at the same time to avoid batch effects. **(L)** Bacterial translocation into peripheral organs on day 2 p.i. in *IL22*^−/−^ mice treated or not with acetate (*n* = 5--6). **(M)** Intestinal permeability of *IL22*^−/−^ mice treated or not with acetate and infected with *C. difficile* (*n* = 5--6). Infected WT mice not treated with acetate are shown as controls. Results are representative of at least two independent experiments with four to six mice in each experimental group (G--I) or pooled results from two independent experiments with three to four mice in each group (A--F). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig6){#fig6}

Since ILC3s produce IL-22, which promotes epithelial cell defense mechanisms and mucus production, we asked whether acetate-mediated protection against CDI depends on IL-22 production. To test this, acetate-treated and untreated mice received an i.p. dose of anti--IL-22 neutralizing antibody or isotype control on day 1 and 3 after CDI ([Fig. 6 G](#fig6){ref-type="fig"}). Neutralization of IL-22 entirely reduced the protective effect of acetate, raising the clinical score and body weight loss of acetate-treated mice to levels comparable to those seen in untreated mice that also received anti-IL-22 ([Fig. 6, H and I](#fig6){ref-type="fig"}). Similarly, beneficial effects of acetate on clinical score, body weight, bacterial translocation, and epithelial permeability during CDI were strongly reduced in *Il22*^−/−^ mice ([Fig. 6, J--M](#fig6){ref-type="fig"}). Conversely, newly generated mice with genetic disruption of IL-22 binding protein (*Il22ra2*), which acts as an IL-22 decoy ([@bib19]), were as resistant to CDI as acetate-treated WT mice. Acetate treatment did not further improve CDI resistance of *Il22ra2*^−/−^ mice ([Fig. S4 A](#figS4){ref-type="fig"}). Together, these data highlight the importance of IL-22 production by ILC3s in the protective effect of acetate.

Acetate did not increase IFNγ expression in the colon or IFNγ production by primary ILC3 ex vivo ([Fig. S4, B--D](#figS4){ref-type="fig"}), suggesting no obvious impact on ILC1s. We conclude that ILC3s production of IL-22 has a major role in acetate-induced protection against CDI.

![**Acetate-mediated protection during CDI involves IL-22 secretion by ILC3s. (A)** Clinical score, body weight variations, and intestinal permeability of *Il22ra2*^−/−^ and WT mice that were treated (Ac) or not (Ct) with acetate and infected with *C. difficile* (*n* = 5--6). **(B)** *Ifng* mRNA expression in the colon of WT mice on day 2 p.i. that were treated or not with acetate (*n* = 5). **(C)** IFNγ production by primary ILC3s ex vivo (*n* = 5). Cells were directly treated with *C. difficile* supernatant ± acetate. **(D)** IFNγ secretion by primary ILC3s incubated with neutrophil supernatants. Neutrophils were stimulated with LPS+ *C. difficile* supernatant (Nφ sup); LPS+ *C. difficile* supernatant and acetate (Nφ + Ac sup); and LPS+ *C. difficile* supernatant and FFAR2 agonist (Nφ + Ffar2 ag sup; *n* = 5). **(E)** IL-22--producing MNK3 cells after 3 h of treatment with different combinations of acetate and IL-1β, as indicated (*n* = 5). ns, not significant. **(F--H)** *Ffar2* and *Ffar3* mRNA expression in the colon of WT mice on day 5 p.i. (F; *n* = 7--8); MNK3 cells after incubation with acetate (G; *n* = 5--6); and FACS sorted-ILC3s from antibiotic-treated mice (H; day 0, before CDI). Mice were either treated or not with acetate in the drinking water (*n* = 4). **(I)** Gating strategy used to identify primary ILC3s from the small intestine of WT mice (Bando et al., 2018; Robinette et al., 2017). SSC, side scatter. **(J)** Percentage of CCR6^+^NKp46^−^ (LTi), CCR6^−^NKp46^−^, CCR6^−^NKp46^+^ subsets within primary ILC3s treated ex vivo with neutrophil supernatants. A representative flow cytometry plot depicting the strategy to identify the subsets is presented on the left. Results are representative of at least two independent experiments with two to five mice in each experimental group (A--F) or are pooled from two independent experiments with three to five mice in each experimental group (F--I). Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_FigS4){#figS4}

Acetate-FFAR2 signaling augments IL-22 production by increasing ILC3 responsiveness to neutrophil-derived IL-1β {#s10}
---------------------------------------------------------------------------------------------------------------

Since ILC3s express FFAR2, and acetate protection was dependent on these cells and FFAR2, we decided to test the direct effect of acetate on the production of IL-22. We incubated primary ILC3s in vitro with acetate, *C. difficile* supernatant, and IL-23 and measured the percentage of IL-22--producing cells by intracellular staining. Acetate had no impact on IL-22 production in these cultures ([Fig. 7 A](#fig7){ref-type="fig"}). Similar results were obtained using the ILC3 line MNK3 ([@bib2]; [Fig. 7 B](#fig7){ref-type="fig"}). However, the percentage of IL-22--producing ILC3s was increased in acetate-treated mice 5 d p.i. ([Fig. 7 C](#fig7){ref-type="fig"}). Similarly, acetate treatment increased the expression of IL-22 mRNA in ILC3s FACS sorted from antibiotic-treated mice ([Fig. 7 D](#fig7){ref-type="fig"}). It is known that ILC3s secrete IL-22 in response to IL-1β and IL-23 ([@bib45]; [@bib52]). We sought to determine whether acetate stimulated ILC3s indirectly through enhanced expression of IL-23 receptor or IL-1R. We found that acetate increased the expression of IL-1R in (a) MNK3 cells ([Fig. 7, E and F](#fig7){ref-type="fig"}); (b) primary ILC3s isolated from *C. difficile*--infected mice 5 d p.i. ([Fig. 7 G](#fig7){ref-type="fig"}); (c) primary ILC3s isolated from antibiotic-treated mice ([Fig. 7 H](#fig7){ref-type="fig"}); and (d) primary ILC3s treated with acetate in vitro ([Fig. 7 I](#fig7){ref-type="fig"}). These results suggested that acetate may increase ILC3 responsiveness to IL-1β. To confirm that IL-1R expression is induced by acetate via FFAR2, we assessed the impact of synthetic FFAR2 agonist and antagonist on the stimulatory activity in primary ILC3s. FFAR2 agonist increased the percentages of IL-1R--expressing primary ILC3s, as did acetate, while FFAR2 antagonist inhibited such effect ([Fig. 7 I](#fig7){ref-type="fig"}). To corroborate that acetate increases the responsiveness of ILC3s to IL-1β, we examined IL-22 production of FACS sorted-ILC3s ([Fig. 7 J](#fig7){ref-type="fig"}) and MNK3 cells ([Fig. S4 E](#figS4){ref-type="fig"}) stimulated in vitro with different combinations of acetate and IL-1β. Acetate-FFAR2 signaling clearly enhanced the percentage of IL-22--producing cells induced by IL-1β ([Fig. 7 J](#fig7){ref-type="fig"}). Further, we also found that acetate does not change the expression of *Ffar2* and *Ffar3* in the colon of mice 5 d p.i. ([Fig. S4 F](#figS4){ref-type="fig"}), as well as both MNK3 ([Fig. S4 G](#figS4){ref-type="fig"}) and ILC3s FACS-sorted from antibiotic-treated mice ([Fig. S4 H](#figS4){ref-type="fig"}).

![**Acetate enhances ILC3 production of IL-22 by increasing their responsiveness to neutrophil IL-1β.** **(A)** Percentages of IL-22--producing primary ILC3s incubated ex vivo with *C. difficile* supernatant, IL-23, and acetate as indicated (*n* = 5). **(B)** Percentages of IL-22--producing MNK3 cells incubated with *C. difficile* supernatant and/or IL-23, ± acetate, as indicated (*n* = 5). **(C)** Percentages of IL-22--producing ILC3s from *C. difficile*--infected mice on day 5 p.i. (*n* = 8). Cells were stimulated with Golgi plug and IL-23 (10 ng/ml) ± IL-1β (1 ng/ml) for 3 h. **(D)** *Il22* mRNA expression of ILC3s FACS sorted from antibiotic-treated mice (day 0, before CDI). Mice were either treated (Ac) or not (Ct) with acetate in the drinking water (*n* = 4). **(E and F)** Percentages of IL-1R--expressing MNK3 cells (E) and *Il1r* mRNA expression (F) after incubation with *C. difficile* supernatant and/or IL-23 ± acetate (*n* = 5--6). Representative plots are presented on the left. Blank, control antibody; SSC, side scatter. **(G)** Percentages of IL-1R--expressing ILC3s from *C. difficile*--infected mice on day 5 p.i. (*n* = 8). **(H)** *Il1r* mRNA expression by FACS-sorted ILC3s from antibiotic (abx)-treated mice. Mice were either treated or not with acetate (*n* = 4). **(I)** Percentages of IL-1R--expressing primary ILC3s after ex vivo treatment with acetate, Ffar2-agonist, and Ffar2-antagonist, as indicated (*n* = 5). **(J)** IL-22--producing cells within sorted ILC3s treated with different combinations of acetate, IL-1β, Ffar2-agonist, or Ffar2-antagonist, as indicated (*n* = 5). Results are representative of at least two independent experiments with three to four mice/replicates in each group (A and I--K) or pooled results from two independent experiments with two to five mice/replicates in each one (B--H). All mice used were littermates. Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig7){#fig7}

Acetate promotes neutrophil-ILC3 cross-talk through IL-1β {#s11}
---------------------------------------------------------

We sought to directly demonstrate that acetate activates primary ILC3s through IL-1β produced by neutrophils. We isolated ILC3s from the intestinal lamina propria of *Rag1*^−/−^ mice, which lack T and B cells, and incubated them ex vivo with IL-23 together with culture supernatants from neutrophils that had been stimulated with LPS and *C. difficile* toxins, with or without acetate, or with synthetic FFAR2 agonist ([Fig. 8 A](#fig8){ref-type="fig"}). ILC3s stimulated with supernatant of neutrophils treated with acetate or FFAR2 agonist produced more IL-22 than did ILC3s cultured with supernatant of neutrophils treated with LPS and *C. difficile* toxins only. This effect could be blocked with a neutralizing anti-IL-1β antibody, but not by a FFAR2 antagonist ([Fig. 8 A](#fig8){ref-type="fig"}), demonstrating that ILC3 production of IL-22 is induced by neutrophil-derived IL-1β and not FFAR2 activation of ILC3s. In contrast to the stimulating effect on cytokine secretion, the supernatant of neutrophils had no impact on the abundance of total ILC3s or any of the CCR6^+^NKp46^−^, CCR6^−^NKp46^−^, or CCR6^−^NKp46^+^ subsets included in the ILC3 population purified from the intestine using a standard cell sorting protocol ([Fig. S4, I and J](#figS4){ref-type="fig"}).

![**Acetate promotes neutrophil**--**ILC3 cross-talk through IL-1β.** **(A)** Percentages of IL-22--producing primary ILC3s that were isolated from *Rag1*^−/−^ mice and triggered in vitro with IL-23 and supernatant of neutrophils in the indicated combinations. Neutrophils were stimulated as follows: Nφ sup, LPS + *C. difficile* supernatant; Nφ + Ac sup, LPS + *C. difficile* supernatant + acetate; Nφ + Ffar2 ag sup: LPS + *C. difficile* supernatant + Ffar2-agonist. Anti--IL-1β blocking antibody or Ffar2-antagonist (antag.) was added, as indicated. Representative flow cytometry plots are presented on the left (*n* = 4). Top: Stimulations with IL-23 or neutrophil supernatant only. Middle: Stimulations combining IL-23 and various neutrophil supernatants. Bottom: Addition of anti--IL-1β or Ffar2 antagonist. SSC, side scatter. **(B)** Clinical score and body weight variation of *Ffar2^fl/fl^* and *Ffar2^ΔS100^* (*Ffar2^fl/fl^* × *S100*-Cre) mice that were treated with acetate and infected with *C. difficile* (*n* = 4--5). *Ffar2^ΔS100^* and *Ffar2^fl/fl^* littermates were infected at the same time. **(C and D)** *Il22*, *Ror**c***, *I**l**1**b*** (C), and IL-22 target genes mRNA expression (D) in the colon of acetate-treated *Ffar2^fl/fl^* and *Ffar2^ΔS100^* mice on day 5 p.i. (*n* = 4--5). Results are representative of at least two independent experiments with three to four mice in each (A) or pooled results from two independent experiments with two to three mice in each group (B--D). All mice used were littermates. Results are presented as mean ± SEM. \*, P \< 0.05.](JEM_20190489_Fig8){#fig8}

Finally, examination of mice with a deletion of the *Ffar2* gene in neutrophils (*Ffar2^ΔS100^*) provided in vivo demonstration that acetate-mediated protection against CDI depends on neutrophils. The beneficial effect of acetate treatment on clinical score and weight change in CDI was reduced in *Ffar2^ΔS100^* mice compared with *Ffar2^f/f^* mice ([Fig. 8 B](#fig8){ref-type="fig"}). Notably, *Ffar2^ΔS100^* mice exhibited no clinical recovery on day 5 in contrast to *Ffar2^f/f^* mice. Moreover, acetate-treated *Ffar2^ΔS100^* mice showed decreased expression of *Il22*, *Rorc*, and *Il1b* in the colon compared with acetate-treated *Ffar2^f/f^* mice 5 d p.i. ([Fig. 8 C](#fig8){ref-type="fig"}), as well as reduced expression of IL-22 target genes (*Bcl2*, *Ccnd1*, *Reg3g*, and *Muc1*) in the colon ([Fig. 8 D](#fig8){ref-type="fig"}), demonstrating that ILC3-mediated protection during CDI is at least in part due to acetate-FFAR2 mediated activation of neutrophils. Altogether, these data corroborate that acetate protects from CDI by promoting neutrophil-ILC3 cross-talk through IL-1β.

Discussion {#s12}
==========

The presence of commensal gut microbiota is essential to suppress *C. difficile* expansion and pathogenicity ([@bib5]; [@bib25]; [@bib27]). Our study demonstrates that the protective impact of the microbiota depends at least in part on the production of acetate through fiber fermentation, which activates the FFAR2 signaling pathway in both neutrophils and ILC3s coordinating their protective functions. Acetate-FFAR2 signaling in neutrophils enhances inflammasome-mediated secretion of active IL-1β, which provides a first line of defense against *C. difficile* toxins. Acetate-FFAR2 signaling in ILC3s augments expression of IL-1R, and the elevated levels of IL-1R boost IL-1β--induced production of IL-22, which elicits antimicrobial and repair mechanisms in intestinal epithelial cells. Thus, microbiota-derived acetate promotes coordinate activation of neutrophils and ILC3s through FFAR2, which bolsters host innate inflammatory and repair responses to *C. difficile.*

By using newly generated *Ffar2^ΔS100^* mice, we conclusively demonstrated that acetate provides protection against CDI by activating neutrophil FFAR2. Since FFAR2 acts as a chemotactic receptor ([@bib40]; [@bib51]), its engagement by acetate may be important to increase the initial recruitment of neutrophils after CDI and/or their survival at *C. difficile*--damaged sites. Moreover, we found that acetate-FFAR2 signaling augmented IL-1β production by neutrophils in response to *C. difficile* toxin--mediated activation of the inflammasome. Indeed, the impact of acetate on IL-1β was negligible in *Ffar2*^−/−^ as well as *Casp1/11*^−/−^ and *Nlrp3*^−/−^ mice. How acetate-FFAR2 signaling enhances *C. difficile* toxin--induced inflammasome activation remains to be investigated. It is possible that acetate-FFAR2 signaling facilitates K^+^ efflux and/or Ca^2+^ influx that trigger NLRP3 activation. Consistent with this, engagement of FFAR2 on colonic epithelial cells by acetate was shown to stimulate NLRP3 through Ca^2+^ influx and cell hyperpolarization ([@bib29]). Acetate-FFAR2 signaling may also activate other downstream mediators that interact with inflammasomes, such as microfilaments, tubulin, and protein kinase C μ--dependent integrin-linked kinase, as shown for other G protein--coupled receptors that impact inflammasome activation ([@bib4]). Although not tested in our study, acetate may also enhance pyrin inflammasome activation in response to *C. difficile* toxins. While inflammasome activation was mainly detected in neutrophils, we do not exclude that intestinal macrophages may contribute to caspase-1--mediated IL-1β production. We also noticed that acetate can enhance caspase-1--mediated production of IL-18. This effect may be relevant in other models of colitis, such as dextran sulfate sodium--induced colitis, in which IL-18 has a prominent role in promoting epithelial repair ([@bib29]).

In addition to boosting the IL-1β response, acetate enhanced IL-22 response during CDI. IL-22 promotes antimicrobial and repair mechanisms in epithelial cells ([@bib34]; [@bib35]), as well as systemic immune responses via activation of the C3 complement pathway ([@bib18]). IL-22 induction contributed considerably to the overall protection mediated by acetate, which indeed was markedly reduced in *Il22*^−/−^ mice, as well as WT mice treated with a neutralizing anti-IL-22 antibody. We confirmed a previous report that ILC3s are a major source of IL-22 during CDI ([@bib1]) and demonstrated that mice specifically lacking ILC3s have a defect in control of the acute phase and in the resolution of CDI. We further examined how acetate induces IL-22 in ILC3s. Although ILC3s express FFAR2, we found no direct effect of acetate-FFAR2 signaling on IL-22 production. However, the acetate-FFAR axis enhanced ILC3 expression of IL-1R, thereby heightening ILC3 sensitivity to IL-1β, a known inducer of IL-22 that is produced by neutrophils during CDI and perhaps by other myeloid cells. Thus, acetate stimulates IL-22 through a coordinate increase in IL-1β bioavailability and ILC3 responsiveness to IL-1β. These results complement the recent observation that FFAR2 signaling promotes in situ proliferation of colonic ILC3 ([@bib7]). It was shown that butyrate, but not acetate or propionate, suppresses ILC2 function and ameliorates ILC2-driven airway inflammation through histone deacetylase inhibition and H3 acetylation, independent of FFAR2 and FFAR3 ([@bib48]). Whether acetate impacts epigenetic regulation of ILC3s, neutrophils, or other immune cells responding to *C. difficile* remains to be explored.

Currently, the first line treatment for *C. difficile*--infected patients includes vancomycin, fidaxomicin, and/or metronidazole ([@bib31]). However, patients suffer relapsing disease refractory to standard antibiotic treatment benefit from fecal transplant ([@bib31]). Our discovery of the impact of acetate treatment on CDI in mice may further contribute to innovate the treatment of *C. difficile*. Future studies will be necessary to determine whether acetate is similarly effective in humans. In summary, our data demonstrate a marked protective effect of microbial-derived acetate against CDI and show that acetate activates FFAR on both neutrophils and ILC3s, resulting in a coordinate increase of inflammasome-induced production of IL-1β in neutrophils and responsiveness to IL-1β in ILC3s. Overall, this study highlights the considerable impact and the complex mechanisms of action of intestinal microbiota metabolites in the control of dysbiosis and intestinal infections.

Materials and methods {#s13}
=====================

Mice {#s14}
----

8-wk-old C57BL/6, *Rag2/Il2rg*-deficient, *Rag1*^−/−^, and *S100*-Cre male mice were purchased from Jackson Laboratory or the Multidisciplinary Centre for Biological Investigation. *Caspase1/11*, *Nlpr3*, and *Rag2*-deficient mice were purchased from the Centre for Development of Experimental Models for Medicine and Biology of the Federal University of Sao Paulo. *Nlrp6*^−/−^, *Nlrc4*^−/−^, *Il22*^−/−^, and *Ffar2*^−/−^ mice were provided by our collaborators from the Institute of Biological Science of the Federal University of Minas Gerais. *AhR^fl/fl^ RorcCre* mice were previously reported ([@bib41]). *Ffar2^fl/fl^* mice were provided by our collaborator from the University of Illinois at Chicago, IL. All strains were maintained in a C57BL/6 background and were kept in regular filter-top cages with free access to sterile water and food. Animal procedures were approved by the Ethics Committee on Animal Use of the Institute of Biology (protocol numbers 3230-1, 3742-1, and 4886-1) and by Washington University Animal Studies Committee.

Generation of Il22ra2 (IL-22 binding protein) null LacZ and floxed mice {#s15}
-----------------------------------------------------------------------

To generate Il22ra2^tm1b^ (null LacZ) and Il22ra2^tm1c^ (flox) mice, two Il22ra2^tm2a(EUCOMM)Wtsi^ ES cell clones (ES line JM8A3.N1) were obtained from European Conditional Mouse Mutagenesis Consortium; one correctly targeted clone, confirmed by Southern blot analysis, was introduced into B6-albino (C57BL/6J-Tyr^c-2J^/J) eight-cell embryos by laser-assisted injection. Male chimeras were initially bred to B6-albino mice to assess germline transmission; those transmitting were bred to CMV-Cre transgenic mice (B6.C-Tg(CMV-Cre)1Cgn/J; \>99% C57BL/6) to delete exon 3 of Il22ra2 and the neomycin-resistance cassette. To delete lacZ as well as the neomycin-resistance cassette and generate mice with loxP sites flanking exon 3 of Il22ra2, chimeras were bred to CAG-FLPe C57BL/6 mice. The CMV-Cre and FLPe transgenes were subsequently bred out of the lines.

Bacteria {#s16}
--------

Toxigenic *C. difficile* VPI 10463 strain was cultivated in brain-heart infusion (BHI) blood agar supplemented with hemin (5 µg/ml) and menadione (1 µg/ml) at 37°C in anaerobic atmosphere (AnaeroGen, Oxoid; Thermo Fisher Scientific) in jars.

Cells {#s17}
-----

Human colon carcinoma cells (HCT116) were cultivated in DMEM supplemented with 10% FBS, 2 mM [l]{.smallcaps}-glutamine, 100 U ml^−1^ penicillin, and 100 µg/ml streptomycin (Vitrocell Embriolife) until the 10th passage. The MNK3 cell line was previously described and provides an attractive in vitro system to study the function of ILC3/LTi cells ([@bib2]). MNK3 cells were cultured in DMEM with 10% FBS, 2 mM GlutaMAX, 1 mM sodium pyruvate, 55 µM 2-mercaptoethanol, 50 µg/ml gentamicin, and 10 mM Hepes, from HyClone with 4% IL-7 and 2% IL-2.

Model of infection {#s18}
------------------

Mice infections were performed as previously described ([@bib6]). Mice were pretreated with antibiotic mixture (0.4 mg/ml kanamycin, 0.035 mg/ml gentamicin, 0.035 mg/ml colistin, 0.215 mg/ml metronidazole, and 0.045 mg/ml vancomycin; Sigma-Aldrich) added to drinking water for 4 d. Next, mice received clindamycin (10 mg/kg, i.p.; Sigma-Aldrich). After 1 d, mice were infected with 10^8^ CFU of *C. difficile* by gavage. Mice were weighed and monitored daily during the entire protocol with a clinical severity score that varied from 0 (normal) to 15, as described ([@bib28]; Table S1).

###### Clinical score

  Category    Score                                                                          
  ----------- -------- ----------------------------------- --------------------------------- -----------------------------
  Activity    Normal   Alert/slow moving                   Lethargic/shaky                   Inactive unless prodded
  Posture     Normal   Back slanted                        Hunched                           Hunched/nose down
  Coat        Normal   Piloerection                        Rough skin                        Very ruffled/puff/ungroomed
  Diarrhea    Normal   Soft stool/discolored (yellowish)   Wet stained tail/mucous ± blood   Liquid/no stool (ileus)
  Eyes/nose   Normal   Squinted/half closed                Squinted/discharge                Closed/discharge

Clinical score = sum of all parameter scores. Total possible score is 15.

Diets and acetate treatment {#s19}
---------------------------

Animals received oral pretreatment with acetate at 150 mM or placebo in the drinking water, as reported in other studies ([@bib50]). Acetate treatment started 1 d before addition of antibiotics and continued throughout the protocol. Acetate solution was prepared using acetic acid (Sigma-Aldrich) at a concentration of 1.5 M in water (stock solution 10×, pH adjusted to 7.2--7.4, filtered at 0.22 µm). Mice had ad libitum access to water and food during the entire protocol. In dietary experiments, mice were maintained in diets with different amounts of fiber: a control diet, based on American Institute of Nutrition (AIN93) recommendations containing 5% cellulose; and a diet that in addition to 5% cellulose was supplemented with 10% of soluble fiber pectin from citrus ([@bib50]). Mice were prefed with the different diets for 21 d ([Fig. 1 A](#fig1){ref-type="fig"}).

Measurement of SCFAs {#s20}
--------------------

Blood samples were harvested from mice, and the serum was used for measurement of SCFA concentration. Samples were prepared as previously described ([@bib13]). Chromatographic analyses were performed using a GCMS-QP2010 Ultra mass spectrometer (Shimadzu; Thermo Fisher Scientific) and a 30 m × 0.25 mm fused-silica capillary Stabilwax column (Restek Corp.) coated with 0.25 µm polyethylene glycol. Samples (100 µl) were injected at 250°C using a 25:1 split ratio. High-grade pure helium was used as carrier gas at 1.0 ml/min constant flow. Mass conditions were as follows: ionization voltage, 70 eV; ion source temperature, 200°C; full scan mode, 35--500 m/z with 0.2-s scan velocity. The runtime was 11.95 min.

Determination of fecal bacterial load {#s21}
-------------------------------------

Fecal samples (50 mg) were used for extraction of microbial genomic DNA using the PureLink Microbiome DNA Purification kit (Thermo Fisher Scientific). For bacterial load measurement, DNA was quantified by quantitative PCR (qPCR) using primers complementary to Eubacteria 16S rDNA conserved region (E338F sense 5′-ACT​CCT​ACG​GGA​GGC​AGC​AGT-3′ and U1407R anti-sense 5′-ATT​ACC​GCG​GCG​GCT​GCT​GGC-3′; [@bib59]). A standard curve was constructed with serial dilutions of *Escherichia coli* genomic DNA. Results were normalized by percentage of the control.

*C. difficile* in vitro assay {#s22}
-----------------------------

For the in vitro assay with *C. difficile* and acetate, bacteria were cultured 3 d earlier on BHI blood agar supplemented with hemin (5 µg/ml) and menadione (1 µg/ml) in anaerobic chamber at 37°C. Initially, bacteria were resuspended and washed twice with sterile PBS. After that, the bacterial concentration was adjusted and maintained at 0.5 × 10^7^ CFU/ml in a final volume of 5 ml BHI broth with or without acetate at different concentrations. Cultures were incubated for 72 h in anaerobiosis at 37°C and had the optical density of the medium read at 600 nm wavelength. To verify possible contaminations of the liquid culture, the medium was plated on BHI blood agar, and bacterial growth and gram staining of the colonies were observed.

Histological analysis {#s23}
---------------------

Mouse colons were harvested, opened longitudinally, and fixed in 4% formalin/0.1% glutaraldehyde. Tissues were processed into historesin, and 5-µm sections were prepared for staining with hematoxylin and eosin or Giemsa/Rosenfeld solution. Slides were analyzed using an Olympus microscope (model U-LH100HG). Samples were analyzed blindly using histological scores for each parameter (Table S2). Overall scores were the sums of each component and varied from 0 to 30.

###### Histological score

  Category                 Finding                  0 (none)      1 (mild)            2 (moderate)            3 (severe)
  ------------------------ ------------------------ ------------- ------------------- ----------------------- --------------------------
  Mucosal epithelium       Ulceration               None          Mild surface        Moderate                Extensive full thickness
  Crypts                   Mitotic activity         Lower third   Mild middle third   Moderate middle third   Upper third
  Mucus depletion          None                     Mild          Moderate            Severe                  
  Lamina propria           Mononuclear infiltrate   None          Mild                Moderate                Severe
  Granulocyte infiltrate   None                     Mild          Moderate            Severe                  
  Vascularity              None                     Mild          Moderate            Severe                  
  Fibrin deposition        None                     Mucosal       Submucosal          Transmural              
  Submucosal               Mononuclear infiltrate   None          Mild                Moderate                Severe
  Granulocyte infiltrate   None                     Mild          Moderate            Severe                  
  Edema                    None                     Mild          Moderate            Severe                  

Histological score = sum of all parameter scores. Total possible score is 30.

Analysis of neutrophil population {#s24}
---------------------------------

The lamina propria of the colon was collected and processed for neutrophil analysis. First, the colon was extracted and washed twice with 1× HBSS supplemented with 5% FBS and 2 mM EDTA in a 50-ml Falcon tube under horizontal shaking in an orbital mixer at 250 rpm for 20 min at 37°C. Then, enzymatic digestion was performed in solution containing 1× HBSS supplemented with 2 mM EDTA and collagenase IV (40 U/ml) at 200 rpm for 15 min at 37°C. The obtained cells were then separated from the tissue using a 70-µm filter (Cell Strainer; BD Bioscience). Samples were counted in Neubauer's chamber, and 10^6^ cells were labeled with specific antibodies coupled to different fluorochromes and analyzed by flow cytometry. Anti-Ly6G FITC (Gr-1) clone 1A8-Ly6g, anti-Ly6C PE clone HK1.4, and anti-CD11b APC clone M1/​​70 anti-mouse antibodies (eBioscience, Thermo Fisher Scientific) were used for analysis of the neutrophil population on the lamina propria. Data were analyzed using FlowJo software.

Measurement of cytokines in tissues {#s25}
-----------------------------------

Colon samples (100 mg) were homogenized in PBS containing protease inhibitors (Thermo Fisher Scientific). Samples were centrifuged for 10 min at 2,000 *g*, and supernatants used for measurement of IL-1β, TNF-α, CXCL1, CXCL2, IL-10, IL-22, and IL-18 using the Duo Set ELISA kit (R&D Systems).

Bacterial translocation {#s26}
-----------------------

Spleen, liver, and mLNs were harvested on day 1 or 2 of infection. Bacterial 16S rDNA were extracted using the PureLink Microbiome DNA Purification kit (Thermo Fisher Scientific), and gene levels were quantified by qPCR using primers complementary to Eubacteria 16S rDNA conserved region (Table S3). The bacterial load was determined by a standard curve with serial dilutions of *E. coli* genomic DNA, and the CFU per gram of tissue was determined by dividing gene levels by sample weight.

###### Primers used for qPCR

  Primer                         Sequence (5′ to 3′)
  ------------------------------ ---------------------------------
  **16s of eubacteria**          
  Sense                          ACT​CCT​ACG​GGA​GGC​AGC​AGT
  Antisense                      ATTACCGCGGCTGCTGGC
  **β2-Microglobulin (*B2m*)**   
  Sense                          CCC​CAC​TGA​GAC​TGA​TAC​ATA​CG
  Antisense                      CGA​TCC​CAG​TAG​ACG​GTC​TTG
  ***Il17***                     
  Sense                          TCA​GCG​TGT​CCA​AAC​ACT​GAG
  Antisense                      GAC​TTT​GAG​GTT​GAC​CTT​CAC​AT
  ***Il22***                     
  Sense                          AGA​ATG​TCA​GAA​GGC​TGA​AGG
  Antisense                      AGG​AGC​AGT​TCT​TCG​TTT​TCT​AG
  **ROR-γt (*Rorc*)**            
  Sense                          TCC​ACT​ACG​GGG​TTA​TCA​CCT
  Antisense                      AGT​AGG​CCA​CAT​TAC​ACT​GCT
  ***Il1r***                     
  Sense                          GCA​CGC​CCA​GGA​GAA​TAT​GA
  Antisense                      AGA​GGA​CAC​TTG​CGA​ATA​TCA​A
  ***Il1b***                     
  Sense                          GGC​AGC​TAC​CTG​TGT​CTT​TCC​C
  Antisense                      ATA​TGG​GTC​CGA​CAG​CAC​GAG
  ***Bcl2***                     
  Sense                          TGA​GTA​CCT​GAA​CCG​GCA​TCT
  Antisense                      GCA​TCC​CAG​CCT​CCG​TTA​T
  **Cyclin D1 (*Ccnd1*)**        
  Sense                          GCA​AGC​ATG​CAC​AGA​CCT​T
  Antisense                      GTT​GTG​CGG​TAG​CAG​GAG​A
  ***g3g***                      
  Sense                          TTC​CTG​TCC​TCC​ATG​ATC​AAA​A
  Antisense                      CAT​CCA​CCT​CTG​TTG​GGT​TCA
  ***Muc1***                     
  Sense                          CCC​TAC​CTA​CCA​CAC​TCA​CGG​ACG
  Antisense                      GTG​GTC​ACC​ACA​GCT​GGG​TTG​GT
  ***Muc4***                     
  Sense                          GAG​GGC​TAC​TGT​CAC​AAT​GGA​GGC
  Antisense                      AGG​GTT​CCG​AAG​AGG​ATC​CCG​TAG
  ***Ffar2***                    
  Sense                          GGC​TCC​CTG​CCA​ACC​TGC​TG
  Antisense                      GTG​CAC​AGG​GGC​AGG​CTG​AG
  ***Ffar3***                    
  Sense                          GGG​TTA​CAC​ACA​GAG​GTG​GC
  Antisense                      CAT​CAC​GTT​GAG​GGG​GAG​TC
  **IFNγ (*Ifng*)**              
  Sense                          ATG​AAC​GCA​CAC​ACT​GCA​TC
  Antisense                      CCA​TCC​TTT​TGC​CAG​TTC​CTC

Measurement of intestinal permeability with FITC-dextran {#s27}
--------------------------------------------------------

Mice received 200 µl FITC-dextran (70,000 D; Sigma-Aldrich) suspension (250 mg/kg) by gavage on day 2 of infection. After 4 h, mice were anesthetized, blood was collected by caudal puncture, and fluorescence readings were performed in a Multi-Mode Microplate Reader (Synergy HT) at 485/528 nm (excitation/emission). A standard curve was prepared with serial dilutions of FITC-dextran in PBS.

Epithelial cell culture and live/dead assay {#s28}
-------------------------------------------

Human colon carcinoma cells (HCT116) were cultivated in 1:500 bacterial supernatant and 10, 25, or 50 µM of acetate in 96-well plates (1.0 × 10^5^ cells/well). After 48 h, cells were washed gently using Dulbecco's PBS (DPBS), and medium was replaced by 100 liters Calcein-AM and propidium iodide (2 µM) in DPBS and incubated for 30 min at 37°C under 5% CO~2~. Images were obtained using the Cytation 5 Cell Imaging Multi-Mode Reader, and green fluorescence (485/530 nm, excitation/emission) of viable cells and red fluorescence (530/645 nm) of dead cells were quantified using Gen5 software (Biotek). As a positive control, cells were preincubated with 0.1% Triton X-100 for 15 min. To obtain *C. difficile* supernatants, the toxigenic strain VPI 10463 was cultured 24 h at 37°C in anaerobic conditions in BHI medium supplemented with hemin and menadione. The culture was centrifuged at 10,000 *g* for 5 min, and supernatant was used for treatment of HCT116 culture (1:500 ratio).

Quantitative gene expression {#s29}
----------------------------

Total RNA was extracted from tissue using the PureLink RNA kit (Ambion). RNA was converted to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems), and qPCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) and primers indicated in Table S3. Quantification of gene expression was performed using the 2^ΔΔ\ Ct^ method, with β2-microglobulin as a reference gene.

Neutrophil culture {#s30}
------------------

Bone marrow neutrophils were isolated using a Percoll (GE Healthcare) gradient (55/65%). The purity of this preparation was \>70%. FACS-sorted Ly6G^+^CD11b^+^ cells were also used in some analyses. Cells (4 × 10^6^ cells/ml) were plated at 37°C in RPMI (Vitrocell) containing 10% FBS and without antibiotics. Initially, cells were incubated for 2 h with or without addition of LPS (0.1 µg/ml, *E. coli* 0111:B4) and 25 mM acetate. *C. difficile* (1:1) or its supernatant (1:500) was then added to the culture for 4 h. Subsequently, IL-1β cytokine released in the culture was quantified by ELISA. To elucidate the pathways of acetate on inflammasome activation, after incubation in vitro with LPS ± acetate, neutrophils were treated with a known inflammasome activator, the potassium (K^+^) ionophore nigericin (1 µM), or with BAPTA-AM (25 µM), which inhibits NLRP3 by blocking Ca^2+^ influx, ± *C. difficile* culture supernatant (1:500). Similarly, neutrophils were followed by stimulation with extracellular KCl (45 mM), which inhibits NLRP3 by blocking K^+^ efflux, or NaCl (45 mM), which boosts inflammasome activation by promoting K^+^ efflux. We also performed an experiment with either caspase-1 (10 µM Q-VD-Oph) or neutrophil elastase (10 µM Sivelesat sodium salt) inhibitors. To determine the cellular viability of neutrophils, BioLegend's FITC Annexin V Apoptosis Detection Kit with 7-aminoactinomycin D (7-AAD) was used, and the supplier's instructions were followed.

IL-22 in vivo neutralization {#s31}
----------------------------

*C. difficile*--infected mice, treated or not with acetate in the drinking water, received an i.p. dose of 50 µl PBS with 150 g anti-mouse IL-22 neutralizing antibody (clone 8E11; Genentech) or an equivalent amount of isotype control IgG2a (BioXcell) on days 1 and 3 p.i. Mice were clinically evaluated until the fifth day of infection.

ILCs isolation, MNK3, and cytokine detection {#s32}
--------------------------------------------

Adult small intestine or colon samples were harvested from C57BL/6 male mice, and mesenteric adipose tissue, Peyer's patches, and intraepithelial lymphocytes were first removed by dissection and two EDTA extraction washes. Intestinal lamina propria immune cells were isolated using Collagenase 4 (Sigma-Aldrich) digestion (40 min) and were enriched at the interface between a gradient of 40% and 70% of Percoll (GE Healthcare) in HBSS. For functional experiments, small intestine lamina propria cells were cultured in a 96-well plate in complete medium and stimulated ex vivo in the presence of Golgi Plug (BD) for 3 h at 37°C. Following incubation, Live^+^CD45^+^LIN^--^ (CD3^--^CD5^--^CD19^--^B220^--^) CD45^low^Thy1.2^high^ ILC3s were stained for surface molecules, fixed, and stained for intracellular IL-22 (clone Poly5164; BioLegend). For IL-1R expression, cells were stained with anti-mouse CD121a (IL-1R, clone JAMA-147; BioLegend). Data were analyzed using FlowJo software. The MNK3 cell line was previously described ([@bib2]). MNK3 was stimulated and stained for intracellular IL-22 as described for primary ILC3s.

Statistical analysis {#s33}
--------------------

Analyses were performed using GraphPad software 5.0. All data are presented as means ± SEM, and *n* represents the number of samples per group. The exact value of *n* in each experiment is indicated in the corresponding figure legends. Differences were considered significant for P \< 0.05. Results were first analyzed using D'Agostino/Shapiro--Wilk normality tests and compared by Student's *t* test or Mann--Whitney *U* test, as appropriate. For more than two groups, differences were compared by one-way analysis of variance followed by Tukey's post hoc test.

Online supplemental material {#s34}
----------------------------

[Fig. S1](#figS1){ref-type="fig"} shows the relative bacterial load in the feces on days 0 and 2 d p.i., in vitro growth of *C. difficile* after treatment with acetate, and clinical scores and body weight changes of mice treated with acetate after infection and of infected *Nlrp3*^−/−^, *Nlrc4*^−/−^, and *Nlrp6*^−/−^ mice. [Fig. S2](#figS2){ref-type="fig"} shows IL-18 content in the colon of WT and *Casp1/11*^−/−^ and *Ffar2*^−/−^ mice, neutrophils viability before and after in vitro incubation, and IL-1β production by neutrophils isolated from the bone marrow and stimulated in vitro. [Fig. S3](#figS3){ref-type="fig"} shows expression of SCFA receptors in ILC populations, IL-22 target genes expression in the colon 5 d p.i., ILC subsets in the small intestine 5 d p.i., and representative histological sections of colons of ILC3-deficient mice 5 d p.i. [Fig. S4](#figS4){ref-type="fig"} shows clinical scores, body weight changes, and intestinal permeability of IL-22 binding protein--deficient mice (*Il22ra2*^−/−^); effect of acetate on IFNγ production; in vitro treatment of MNK3 cells with acetate and IL-1β; effect of acetate on *Ffar2* and *Ffar3* expression; and ILC3 subsets. Table S1 describes the clinical score criteria used to evaluate infected mice. Table S2 lists all parameters used for histopathological analyses. Table S3 includes a list of primers used to analyze the gene expression by qPCR. Table S4 lists the reagents used in our study.

###### Reagents

  Reagent or resource                                        Source                                                                      Identifier
  ---------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------
  **Antibodies**                                                                                                                         
  Anti-mouse CD11b, APC                                      eBioscience                                                                 Clone M1/70,17-0112-82
  Anti-mouse Ly6G, FITC                                      eBioscience                                                                 Clone 1A8,11-9668-80
  Anti-mouse Ly6C, PE                                        BioLegend                                                                   Clone HK1.4,128007
  Anti-mouse CD45 APC/Cy7                                    BioLegend                                                                   Clone 30-F11,103115
  Anti-mouse CD45 PerCP/Cy5.5                                BioLegend                                                                   Clone 30-F11,103131
  Anti-mouse CD3 PerCP/Cy5.5                                 BioLegend                                                                   Clone 17A2,100217
  Anti-mouse CD5 PerCP/Cy5.5                                 BioLegend                                                                   Clone 53-7.3,100623
  Anti-mouse CD19 PerCP/Cy5.5                                BioLegend                                                                   Clone 6D5,115533
  Anti-mouse B220 PerCP/Cy5.5                                BioLegend                                                                   Clone RA3-6B2,103235
  Anti-mouse CD90.2 (Thy-1.2) FITC                           BioLegend                                                                   Clone 30-H12,105305
  Anti-mouse CD90.2 (Thy-1.2) APC                            BioLegend                                                                   Clone 53-2.1,140311
  Anti-mouse CD196 (CCR6) Brilliant Violet 421               BioLegend                                                                   Clone 29-2L17,129817
  Anti-mouse CD335 (NKp46) PE                                BioLegend                                                                   Clone 29A1.4,137603
  Anti-mouse CD335 (NKp46) PE-Cy7                            BioLegend                                                                   Clone 29A1.4,137617
  Anti-mouse Rorgt APC                                       Thermo Fisher Scientific                                                    Clone B2D,17-6981-82
  Anti-mouse GATA3 Alexa Fluor 488                           eBioscience                                                                 Clone L50-823,560077
  Anti-mouse EOMES PE                                        Thermo Fisher Scientific                                                    Clone Dan11mag,12-4875-82
  Anti-mouse IL22 PE                                         BioLegend                                                                   Clone Poly5164,516404
  Anti-mouse IL22 APC                                        BioLegend                                                                   Clone Poly5164,516409
  Anti-mouse IFNy APC-Cy7                                    eBioscience                                                                 50-5773-82
  Anti-mouse CD121a (IL-1 R, Type I/p80) biotinylated        BioLegend                                                                   JAMA-147,113503
  PE/Cy7 Streptavidin                                        BioLegend                                                                   405206
  Brilliant Violet 421 Streptavidin                          BioLegend                                                                   405226
  IL-1 beta monoclonal anti-mouse                            eBioscience                                                                 16-7012-81
  IL-22 monoclonal anti-mouse neutralizing antibody          Genentech                                                                   Clone 8E11
  *InVivo*MAb mouse IgG2a isotype control                    BioXcell                                                                    Clone C1.18.4,BE0085
  **Bacterial strains**                                                                                                                  
  *C. difficile* VPI 10463                                   Dr. Mário Júlio Ávila Campos (University of São Paulo, São Paulo, Brazil)   N/A
  *E. coli*                                                  Dr. Marcelo Lancelotti (University of Campinas, Campinas, Brazil)           N/A
  **Chemicals, peptides, and recombinant proteins**                                                                                      
  Kanamycin                                                  Sigma-Aldrich                                                               K1876-5G
  Gentamicin                                                 Sigma-Aldrich                                                               G1914-5G, G1397-10ML
  Colistin                                                   Sigma-Aldrich                                                               C4461-100MG
  Metronidazole                                              Sigma-Aldrich                                                               M3761-5G
  Vancomycin                                                 Sigma-Aldrich                                                               V2002-1G
  Clindamycin                                                Sigma-Aldrich                                                               C5269-50MG
  Acetic acid                                                Sigma-Aldrich                                                               A6283-1L
  Pectin fiber diet                                          This paper                                                                  N/A
  Control LFD                                                This paper                                                                  N/A
  BHI agar                                                   Sigma-Aldrich                                                               70138-500G
  BHI broth                                                  Sigma-Aldrich                                                               53286-500G
  Yeast extract                                              Sigma-Aldrich                                                               92144-500G-F
  Hemin                                                      Sigma-Aldrich                                                               H9039-1G
  Menadione                                                  Sigma-Aldrich                                                               M5625-25G
  Formaldehyde solution                                      Sigma-Aldrich                                                               252549-1L
  Glutaraldehyde solution                                    Sigma-Aldrich                                                               G7651-10ML
  Histological historesin                                    Leica                                                                       7592
  Giemsa stain, modified solution                            Sigma-Aldrich                                                               32884-250ML
  Hematoxylin solution, Harris modified                      Sigma-Aldrich                                                               HHS16
  Eosin stain solution 5%                                    Sigma-Aldrich                                                               R03040-74
  Protease inhibitors                                        Thermo Fisher Scientific                                                    78430
  Power SYBR Green PCR Master Mix                            Applied Biosystems                                                          4367659
  RPMI-1640                                                  Vitrocell Embriolife                                                        N/A
  DMEM                                                       Thermo Fisher Scientific                                                    11966-025
  FBS                                                        Corning                                                                     MT35016CV
  [l]{.smallcaps}-Glutamine                                  Sigma-Aldrich                                                               G3126
  Streptomycin sulfate                                       Sigma-Aldrich                                                               S6501
  Penicillin                                                 Sigma-Aldrich                                                               1502701
  GlutaMAX Supplement                                        Thermo Fisher Scientific                                                    35050061
  Sodium pyruvate                                            Sigma-Aldrich                                                               P2256
  β-Mercaptoethanol                                          Sigma-Aldrich                                                               M6250-10ML
  Hepes                                                      HyClone                                                                     SH30237.01
  Deoxyribonuclease I from bovine pancreas                   Sigma-Aldrich                                                               DN25
  0.5 M EDTA, pH 8.0                                         Invitrogen                                                                  AM9261
  [dl]{.smallcaps}-DTT                                       Sigma-Aldrich                                                               D9779
  Collagenase IV                                             Sigma-Aldrich                                                               C5138-500MG
  Tris-HCl                                                   Sigma-Aldrich                                                               T5941-500G
  SDS                                                        Sigma-Aldrich                                                               L3771-100G
  Dulbecco's PBS                                             Sigma-Aldrich                                                               D4031-1L
  Calcein-AM                                                 Sigma-Aldrich                                                               17783-1MG
  Propidium iodide                                           Sigma-Aldrich                                                               P4170-10MG
  Triton X-100                                               Merck Millipore                                                             1086431000
  HBSS 10×                                                   Sigma-Aldrich                                                               H4641-500ML
  Percoll density gradient medium                            Ge Healthcare                                                               17089101
  LPS from *E. coli* 0111:B4                                 Sigma-Aldrich                                                               LPS25
  Nigericin sodium salt                                      Sigma-Aldrich                                                               N7143-10MG
  BAPTA-AM                                                   Thermo Fisher Scientific                                                    B1205
  Sodium chloride                                            Sigma-Aldrich                                                               S9888-500G
  Potassium chloride                                         Sigma-Aldrich                                                               746436-500G
  Recombinant mouse IL-23 protein                            R&D Systems                                                                 1887-ML-010
  Recombinant mouse IL-1β/IL-1F2 protein                     R&D Systems                                                                 401-ML-010
  GPR43 (FFA2) agonist, Calbiochem                           Millipore                                                                   371725-10MG
  GPR43 (FFA2) antagonist, GLPG 0974                         Tocris                                                                      5621
  **Critical commercial assays**                                                                                                         
  PureLink Microbiome DNA Purification                       Thermo Fisher Scientific                                                    A29790
  Duo Set Kit: TNF-α                                         R&D Systems                                                                 DY008
  Duo Set Kit: IL-1β                                         R&D Systems                                                                 DY401
  Duo Set Kit: IL-10                                         R&D Systems                                                                 DY417
  Duo Set Kit: MIP-2 (Cxcl-2)                                R&D Systems                                                                 DY452
  Duo Set Kit: KC (Cxcl-1)                                   R&D Systems                                                                 DY453
  Duo Set Kit: IL-18                                         R&D Systems                                                                 DY122-05
  Duo Set Kit: IL-22                                         R&D Systems                                                                 DY582-05
  Fixation/Permeabilization Solution Kit with BD GolgiPlug   BD Biosciences                                                              555028
  PE Annexin V Apoptosis Detection Kit with 7-AAD            BioLegend                                                                   640934
  **Experimental models: cell lines**                                                                                                    
  HCT-116                                                    Dr. Patrick Varga-Weisz (University of Essex, Colchester, UK)               N/A
  MNK3                                                       This paper                                                                  N/A
  **Experimental models: organisms/strains**                                                                                             
  C57BL/6 male mice                                          CEMIB - UNICAMP                                                             N/A
  *Rag2/Il2rg*-deficient mice                                Jackson Laboratory                                                          Jax\# 014593
  *Rag2*-deficient mice                                      Federal University of Sao Paulo, Brazil                                     N/A
  *Rag1*-deficient mice                                      Washington University School of Medicine, St Louis, MO                      N/A
  *Caspase1/11*-deficient mice                               Federal University of Sao Paulo, Brazil                                     N/A
  *Nlpr3*-deficient mice                                     Federal University of Sao Paulo, Brazil                                     N/A
  *Nlrp6*-deficient mice                                     Federal University of Minas Gerais, Brazil                                  N/A
  *Nlrc4*-deficient mice                                     Federal University of Minas Gerais, Brazil                                  N/A
  *Il22*-deficient mice                                      Federal University of Minas Gerais, Brazil                                  N/A
  *Ffar2*-deficient mice                                     Federal University of Minas Gerais, Brazil                                  N/A
  *AhR* floxed mice                                          Washington University School of Medicine, St Louis, MO                      N/A
  *Ffar2* floxed mice                                        University of Illinois at Chicago, IL                                       N/A
  *S100-*Cre mice                                            Jackson Laboratory                                                          Jax\# 021614
  *Rorc-*Cre mice                                            Jackson Laboratory                                                          Jax\# 022791
  *Il22ra2*-deficient mice                                   This paper                                                                  
  **Oligonucleotides**                                                                                                                   
  Eubacteria 16S rDNA E338F sense and U1407R antisense       [@bib59]                                                                    N/A
  Primers listed in Table S3                                 This paper                                                                  N/A
  **Software and algorithms**                                                                                                            
  GraphPad Prism v5.0                                        GraphPad Software                                                           N/A
  FlowJo LLC v10.1                                           Becton Dickinson                                                            N/A
  FACSDiva                                                   BD Biosciences                                                              N/A
  ImageJ                                                     National Institutes of Health                                               N/A
  Gen5 software                                              Biotek                                                                      N/A
  Applied Biosystems 7500 Real-Time PCR System               Thermo Fisher Scientific                                                    N/A
  **Other**                                                                                                                              
  AnaeroGen Oxoid                                            Thermo Fisher Scientific                                                    AN0025A
  70- and 40-µm cell strainers                               BD Biosciences                                                              CLS431751-50EA
  LIVE/DEAD fixable dead stain                               Thermo Fisher Scientific                                                    L34962
  FITC--dextran                                              Sigma-Aldrich                                                               46944-100MG-F
  Hoechst 33258 solution                                     Thermo Fisher Scientific                                                    62249

N/A, not applicable.
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